Annovis Bio, Inc.

As of June 30, 2026, Annovis Bio Inc carries a market capitalization of 68.94M, placing it among publicly traded companies globally. Its enterprise value stands at 52.54M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Annovis Bio Inc's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Annovis Bio Inc has 42.61M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Annovis Bio Inc maintains a current ratio of 3.47, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -227.74, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 8.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Annovis Bio Inc's stock has declined approximately 48.85% over the past 52 weeks. The 50-day moving average sits at 1.18, while the 200-day moving average is 1.70.

Over the twelve months ended June 30, 2026, Annovis Bio Inc generated - - in revenue and converted that into -43.35M in net income, yielding earnings per share of -1.58. EBITDA reached -43.35M, while operating income came in at -43.35M.

These figures are as of June 30, 2026. Total book value stands at -3.72M, with working capital of 13.72M providing operational flexibility.

Annovis Bio Inc produced -37.94M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -85.36: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -57.06, meaning Annovis Bio Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Annovis Bio Inc has an Altman Z-Score of -17.23, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.